AMRN - Amarin Earnings And Other News: The Good Bad And Ugly Of Biopharma
Amarin reports better than expected financial numbers for second quarter
Amarin Corporation plc (AMRN) announced its second quarter results, and the numbers were better than anticipated. The company also provided updates about its business operations. Amarin is looking to increase the potential of its blockbuster drug VASCEPA in Europe using its in-house commercial organization.
Amarin reported its net total revenue for the quarter at $135.3 million, up from $100.8 million it had reported for the corresponding quarter of the previous year, showing a 34 percent increase. Its net product revenue for the quarter stood at